$2.600
-0.040 (-1.52%)At close
CRVO News
CRVO Events
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod
CervoMed announced that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of FTD. Interim biomarker data from the study will be presented at the 19th CTAD Conference in Boston, Massachusetts, taking place November 16-19.
Selling Stockholders Plan to Sell 10.08M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10.08M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
CervoMed Issues 2.5 Million Shares at $4.00 Each
CervoMed announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the company from the offering are expected to be $10M, before deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
CervoMed Secures New Patent for DLB Treatment
CervoMed announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO, related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients with no substantial Alzheimer's disease-like tau pathology, also known as "pure DLB". The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging, and is expected to provide intellectual property protection into 2042 and potentially longer with patent term extension. The patent is designed to protect the Company's strategy targeting the treatment of patients with pure DLB. Currently, there are no approved treatments for DLB in the United States or European Union.
CervoMed Study Shows Neflamapimod May Improve Basal Forebrain Function in DLB Patients
CervoMed presented placebo-controlled magnetic resonance imaging analyses providing evidence that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies, or DLB. The findings from further analysis of the RewinD-LB Phase 2b clinical trial showed that right basal forebrain volume increased by 3.5% with neflamapimod treatment and decreased by 4.2% with placebo. CervoMed plans to initiate a Phase 3 trial in the second half of 2026. "Atrophy in the basal forebrain is an important driver of clinical symptoms and progression of DLB. Combined with our previously reported data in neflamapimod treated-patients with early AD, where we saw very similar effects on the basal forebrain, these MRI analyses provide strong evidence that neflamapimod is acting on the underlying cause of DLB by reducing basal forebrain atrophy, reinforcing our clinical and biomarker data and enhancing our belief that neflamapimod has the potential to make a meaningful difference for patients with DLB," said John Alam, CEO of CervoMed.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.